Skip to main content

Coated / Hybrid Mesh

Hybrid meshes combine two or more material types — most often a permanent synthetic polymer with a biologic or absorbable component — to retain the long-term mechanical durability of synthetics while attenuating the chronic foreign body response that drives erosion, contraction, and pain.[1][2]

Rationale​

Permanent polypropylene provides excellent long-term mechanical reinforcement but provokes a sustained inflammatory response in the vaginal niche. Biologic and fully absorbable scaffolds integrate well but lack durable strength. Hybrid constructs aim to combine both: the permanent backbone provides lasting support; the biologic / absorbable component promotes constructive tissue remodeling, lowers acute inflammation, and — in the vaginal compartment — reduces mesh exposure.[1][2]

Categories​

1. Partially Absorbable (Synthetic + Absorbable Synthetic)​

Permanent polypropylene knit with absorbable synthetic fibers that degrade over weeks to months, leaving a lighter-weight permanent scaffold.

  • Vypro / Vypro II (Ethicon) — PP knit with polyglactin 910 (Vicryl) multifilaments; polyglactin absorbed by ~90 days, leaving ~28 g/m² PP.[3]
  • Ultrapro (Ethicon) — PP combined with monofilament poliglecaprone 25 (Monocryl); demonstrates low shrinkage and low inflammatory infiltrate in animal models.
  • PP / PLA hybrid (investigational) — PP knit with polylactic acid; preclinical data show biomechanical equivalence to PP at 180 days with higher collagen I deposition.

Mechanistic note. The form of the absorbable component matters. Polyglactin multifilaments (Vypro) reduce acute inflammation; polyglactin coating of PP (vs multifilament addition) may paradoxically promote encapsulating scar and impair incorporation.[4]

Partially-absorbable mesh in transvaginal POP repair​

StudyDesignnFollow-upFinding
Farthmann 2013RCT, PA vs PP for cystocele2003 yrExposure 3.4% PA vs 7.5% PP (trend); POP recurrence slightly higher with PA (NS).[5]
Lensen 2013Retrospective, PA vs non-absorbable56912 moExposure 5% PA vs 12%; reoperation 1% vs 5%.[6]
Quemener 2014Retrospective PA25020 moRe-intervention 8%; exposure 2%; recurrence 1.2%.[7]
Steures 2019RCT, PA mesh vs native tissue16324 moNo anatomic or composite benefit of PA over native tissue; exposure 6%.[8]
Cho 2018Retrospective, PA vs non-absorbable——Comparable complications; better objective outcomes with PA.[9]

Synthesis: partially absorbable meshes consistently show lower exposure than fully non-absorbable mesh in POP repair (3–5% vs 7–12%), but have not demonstrated superiority over native-tissue repair in the only RCT to test that question.[5][6][8]

2. Reinforced Tissue Matrices (Permanent Synthetic + Biologic ECM)​

Newer construct embedding a permanent polymer within decellularized ECM. The biologic layer recruits host cells and biases the remodeling response toward organized collagen; the polymer provides long-term mechanical reinforcement.[2]

OviTex (TELA Bio) — ovine decellularized ECM layered with polypropylene suture weave — is the most-studied product. Most clinical data come from abdominal-wall reconstruction; direct urogynecologic data are lacking and OviTex has not entered routine reconstructive-urology practice.[1][2]

3. Electrospun / Tissue-Engineered Hybrid Scaffolds (Investigational)​

Advanced-manufacturing constructs that biomimick native tissue architecture. Several have direct relevance to functional urology and urogynecology:

  • PLCL / fibrinogen co-electrospun mesh — canine model showed better initial vascularization and tissue organization than PP; in a human trial for anterior POP repair, PLCL/Fg achieved significantly greater Aa-point improvement vs PP at 6 months.[10]
  • Polyurethane / gelatin nanofiber-coated PP — coaxial electrospun PU-gelatin coating of PP eliminated mesh exposure (0% vs exposure with uncoated PP) in a rat POP model with higher collagen content and reduced macrophage infiltration.[11]
  • PCL / PLGA drug-eluting hybrid membranes — 3D-printed PCL with PLGA nanofibers loaded with lidocaine, estradiol, metronidazole, and CTGF; mechanical strength comparable to commercial PP with sustained drug release for ≥ 30 days.[12]
  • Polystyrene / gelatin core-sheath nanofibers — gelatin sheath for hydrophilicity / biocompatibility over PS mechanical core; switched to an accommodation immune phenotype by 2 weeks post-implantation.[13]
  • PCL / CTGF / PEG-fibrinogen + MSCs — PCL meshes with CTGF and seeded mesenchymal stem cells showed durable support, biocompatibility, and no mesh-related complications at 53 weeks in elderly rats (model relevant to postmenopausal POP).[14]
  • Chitosan / PLA / chitosan trilayer — for urethral reconstruction; higher elastic modulus and tensile strength than PLA or Alloderm alone, with enhanced smooth muscle growth and angiogenic potential.[15]
  • Collagen + PLAC (poly(lactic acid-co-ε-caprolactone)) — for bladder regeneration; supported smooth muscle and urothelial cell proliferation with lower inflammatory reaction than PLAC alone in vivo.[16]

Advantages​

  • Reduced foreign body response (biologic / absorbable component attenuates chronic inflammation).[1][2]
  • Lower vaginal mesh exposure with partially absorbable mesh (3–5% vs 7–12% for non-absorbable).[5][6]
  • Maintained mechanical strength from the permanent backbone.[1]
  • Organized collagen remodeling rather than dense scar encapsulation (biologic component).[4]
  • Reduced foreign-body sensation in pooled hernia data (Vypro vs PP).[3]

Limitations​

  • No clear superiority over native-tissue repair for POP. Steures RCT (PA vs native) was negative at 24 months.[8]
  • Possible trend toward higher POP recurrence vs fully non-absorbable mesh, presumably from reduced permanent material.[5]
  • Limited long-term clinical data (most series ≤ 2 yr).
  • Coating method matters — polyglactin coating of PP (vs multifilament addition) may worsen incorporation.[4]
  • Regulatory ceiling: no transvaginal POP mesh — hybrid or otherwise — is currently FDA-approved or marketed for POP in the US.[17]
  • No head-to-head RCTs of reinforced tissue matrices vs standard synthetic mesh in urogynecologic indications.

Current Use in Reconstructive Urology & Urogynecology​

  • Midurethral slings — standard monofilament macroporous PP remains the material of choice; hybrid slings are not in widespread clinical use.[18]
  • Sacrocolpopexy — lightweight PP remains standard; hybrid constructs have not been widely adopted.[17]
  • Transvaginal POP repair — effectively discontinued in many countries; hybrid mesh was explored as a solution to PP exposure but did not change the regulatory landscape.[8][19]
  • Urological reconstruction (bladder augmentation, urethral repair) — tissue-engineered hybrid scaffolds with biologic components and/or stem cells are the most active area of urological hybrid-mesh research; all remain investigational.[15][16][20]

Future Directions​

  • Drug-eluting hybrids incorporating antimicrobials, anti-inflammatories, estrogen, or growth factors.[12][21]
  • 4D-printed patient-specific scaffolds that change shape or properties in response to physiologic stimuli.[21]
  • Cell-seeded hybrid constructs combining synthetic scaffolds with autologous stem cells for organ regeneration.[14][20]
  • Surface-modified PP with electrospun biologic coatings to improve biocompatibility while retaining PP's mechanical track record.[11][22]

See also: Polypropylene Mesh, Absorbable Synthetic Mesh.

References​

1. Reid CM, Jacobsen GR. A Current Review of Hybrid Meshes in Abdominal Wall Reconstruction. Plastic and Reconstructive Surgery. 2018;142(3 Suppl):92S-96S. doi:10.1097/PRS.0000000000004860

2. Sawyer M, Ferzoco S, DeNoto G. A Polymer-Biologic Hybrid Hernia Construct: Review of Data and Early Experiences. Polymers. 2021;13(12):1928. doi:10.3390/polym13121928

3. Gao M, Han J, Tian J, Yang K. Vypro II Mesh for Inguinal Hernia Repair: A Meta-Analysis of Randomized Controlled Trials. Annals of Surgery. 2010;251(5):838-842. doi:10.1097/SLA.0b013e3181cc989b

4. Klinge U, Klosterhalfen B, Müller M, et al. Influence of Polyglactin-Coating on Functional and Morphological Parameters of Polypropylene-Mesh Modifications for Abdominal Wall Repair. Biomaterials. 1999;20(7):613-623. doi:10.1016/s0142-9612(98)00211-7

5. Farthmann J, Watermann D, Niesel A, et al. Lower Exposure Rates of Partially Absorbable Mesh Compared to Nonabsorbable Mesh for Cystocele Treatment: 3-Year Follow-Up of a Prospective Randomized Trial. International Urogynecology Journal. 2013;24(5):749-758. doi:10.1007/s00192-012-1929-2

6. Lensen EJ, Withagen MI, Kluivers KB, Milani AL, Vierhout ME. Comparison of Two Trocar-Guided Trans-Vaginal Mesh Systems for Repair of Pelvic Organ Prolapse: A Retrospective Cohort Study. International Urogynecology Journal. 2013;24(10):1723-1731. doi:10.1007/s00192-013-2098-7

7. Quemener J, Joutel N, Lucot JP, et al. Rate of Re-Interventions After Transvaginal Pelvic Organ Prolapse Repair Using Partially Absorbable Mesh: 20 Months Median Follow-Up Outcomes. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2014;175:194-198. doi:10.1016/j.ejogrb.2013.12.031

8. Steures P, Milani AL, van Rumpt-van de Geest DA, Kluivers KB, Withagen MIJ. Partially Absorbable Mesh or Native Tissue Repair for Pelvic Organ Prolapse: A Randomized Controlled Trial. International Urogynecology Journal. 2019;30(4):565-573. doi:10.1007/s00192-018-3757-5

9. Cho MK, Moon JH, Kim CH. Non-Absorbable and Partially-Absorbable Mesh During Pelvic Organ Prolapse Repair: A Comparison of Clinical Outcomes. International Journal of Surgery. 2018;55:5-8. doi:10.1016/j.ijsu.2018.05.011

10. Wu X, Wang Y, Zhu C, et al. Preclinical Animal Study and Human Clinical Trial Data of Co-Electrospun Poly(L-Lactide-Co-Caprolactone) and Fibrinogen Mesh for Anterior Pelvic Floor Reconstruction. International Journal of Nanomedicine. 2016;11:389-397. doi:10.2147/IJN.S88803

11. Guo T, Hu X, Du Z, et al. Modification of Transvaginal Polypropylene Mesh With Co-Axis Electrospun Nanofibrous Membrane to Alleviate Complications Following Surgical Implantation. Journal of Nanobiotechnology. 2024;22(1):598. doi:10.1186/s12951-024-02872-z

12. Chen YP, Lo TS, Lin YT, et al. Fabrication of Drug-Eluting Polycaprolactone/Poly(lactic-Glycolic Acid) Prolapse Mats Using Solution-Extrusion 3D Printing and Coaxial Electrospinning Techniques. Polymers. 2021;13(14):2295. doi:10.3390/polym13142295

13. Ge L, Li Q, Jiang J, et al. Integration of Nondegradable Polystyrene and Degradable Gelatin in a Core-Sheath Nanofibrous Patch for Pelvic Reconstruction. International Journal of Nanomedicine. 2015;10:3193-3201. doi:10.2147/IJN.S75802

14. Laursen SH, Hansen SG, Taskin MB, et al. Electrospun Nanofiber Mesh With Connective Tissue Growth Factor and Mesenchymal Stem Cells for Pelvic Floor Repair: Long-Term Study. Journal of Biomedical Materials Research Part B. 2023;111(2):392-401. doi:10.1002/jbm.b.35158

15. Abbas TO, Parangusan H, Yalcin HC, et al. Trilayer Composite Scaffold for Urethral Reconstruction: In Vitro Evaluation of Mechanical, Biological, and Angiogenic Properties. Biomedical Materials. 2024. doi:10.1088/1748-605X/ad1c9c

16. Engelhardt EM, Micol LA, Houis S, et al. A Collagen-Poly(lactic Acid-Co-Ɛ-Caprolactone) Hybrid Scaffold for Bladder Tissue Regeneration. Biomaterials. 2011;32(16):3969-3976. doi:10.1016/j.biomaterials.2011.02.012

17. Committee on Practice Bulletins—Gynecology and American Urogynecologic Society. Pelvic Organ Prolapse: ACOG Practice Bulletin, Number 214. Obstetrics and Gynecology. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

18. Kobashi KC, Vasavada S, Bloschichak A, et al. Updates to Surgical Treatment of Female Stress Urinary Incontinence (SUI): AUA/SUFU Guideline (2023). The Journal of Urology. 2023;209(6):1091-1098. doi:10.1097/JU.0000000000003435

19. Tailor V, Digesu A, Swift SE. Update in Transvaginal Grafts: The Role of Lightweight Meshes, Biologics, and Hybrid Grafts in Pelvic Organ Prolapse Surgery. Obstetrics and Gynecology Clinics of North America. 2021;48(3):515-533. doi:10.1016/j.ogc.2021.05.006

20. Duan L, Wang Z, Fan S, Wang C, Zhang Y. Research Progress of Biomaterials and Innovative Technologies in Urinary Tissue Engineering. Frontiers in Bioengineering and Biotechnology. 2023;11:1258666. doi:10.3389/fbioe.2023.1258666

21. Farmer ZL, Domínguez-Robles J, Mancinelli C, Larrañeta E, Lamprou DA. Urogynecological Surgical Mesh Implants: New Trends in Materials, Manufacturing and Therapeutic Approaches. International Journal of Pharmaceutics. 2020;585:119512. doi:10.1016/j.ijpharm.2020.119512

22. Shiroud Heidari B, Dodda JM, El-Khordagui LK, et al. Emerging Materials and Technologies for Advancing Bioresorbable Surgical Meshes. Acta Biomaterialia. 2024;184:1-21. doi:10.1016/j.actbio.2024.06.012